La Epigrafía griega y latina en la enseñanza de las materias de Filología Clásica: aplicación de nuevas metodologías y nuevas tecnologías (II)

El proyecto PIMCD 2017/18-42 es continuación de dos proyectos anteriores, PIMCD 2011/12-314 y PIMCD 2016/17-5. Su finalidad es familiarizar a los alumnos con diversas cuestiones de la epigrafía griega y latina mediante una serie de unidades didácticas expuestas en un Seminario abierto, cuyas sesiones se celebran en la Facultad de Filología de la UCM

La Epigrafía griega y latina en la enseñanza de las materias de Filología Clásica: aplicación de nuevas metodologías y nuevas tecnologías (VII)

Este proyecto es continuación de varios proyectos INNOVA concedidos anteriormente. La epigrafía es una disciplina fundamental para el conocimiento del mundo antiguo en todas sus manifestaciones: religión, sociedad e instituciones, literatura, lengua, etc. En efecto, gracias a las inscripciones podemos acceder a las fuentes antiguas de manera más inmediata y directa, libres de las posibles modificaciones de la transmisión posterior. En suma, tanto Grecia como Roma fueron civilizaciones en las que las inscripciones desempeñaron una importante función en todos los ámbitos. El propósito de este proyecto ha sido ofrecer a los estudiantes, no solo de Filología Clásica, sino también de Historia y del Doble Grado, una aproximación a estas civilizaciones a través de las técnicas epigráficas.Depto. de Filología ClásicaFac. de FilologíaFALSEsubmitte

La Epigrafía griega y latina en la enseñanza de las materias de Filología Clásica: aplicación de nuevas metodologías y nuevas tecnologías (III)

El objeto de este proyecto es familiarizar con la epigrafía griega y la epigrafía latina a los alumnos de Filología Clásica y a todos aquellos interesados en el mundo antiguo. En el desarrollo de este proyecto se aplicarán las nuevas metodologías y las nuevas tecnologías existentes en este campo

La epigrafía griega y latina en la enseñanza de las materias de Filología Clásica: aplicación de nuevas metodologías y nuevas tecnologías (VI)

El objeto principal de este proyecto INNOVA es la elaboración de material docente de epigrafía griega y latina en forma de unidades didácticas elaboradas por los miembros del proyecto e impartidas en un seminario abierto celebrado a lo largo del curso 2021-2022. Estos seminarios están reconocidos como actividades de carácter formativo para los alumnos de dos programas de Doctorado (“Estudios en el mundo antiguo” e “Historia y Arqueología”

The association between SARS-CoV-2 infection and preterm delivery: a prospective study with a multivariable analysis.

To determine whether severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, the cause of COVID-19 disease) exposure in pregnancy, compared to non-exposure, is associated with infection-related obstetric morbidity. We conducted a multicentre prospective study in pregnancy based on a universal antenatal screening program for SARS-CoV-2 infection. Throughout Spain 45 hospitals tested all women at admission on delivery ward using polymerase-chain-reaction (PCR) for COVID-19 since late March 2020. The cohort of positive mothers and the concurrent sample of negative mothers was followed up until 6-weeks post-partum. Multivariable logistic regression analysis, adjusting for known confounding variables, determined the adjusted odds ratio (aOR) with 95% confidence intervals (95% CI) of the association of SARS-CoV-2 infection and obstetric outcomes. Preterm delivery (primary), premature rupture of membranes and neonatal intensive care unit admissions. Among 1009 screened pregnancies, 246 were SARS-CoV-2 positive. Compared to negative mothers (763 cases), SARS-CoV-2 infection increased the odds of preterm birth (34 vs 51, 13.8% vs 6.7%, aOR 2.12, 95% CI 1.32-3.36, p = 0.002); iatrogenic preterm delivery was more frequent in infected women (4.9% vs 1.3%, p = 0.001), while the occurrence of spontaneous preterm deliveries was statistically similar (6.1% vs 4.7%). An increased risk of premature rupture of membranes at term (39 vs 75, 15.8% vs 9.8%, aOR 1.70, 95% CI 1.11-2.57, p = 0.013) and neonatal intensive care unit admissions (23 vs 18, 9.3% vs 2.4%, aOR 4.62, 95% CI 2.43-8.94, p  This prospective multicentre study demonstrated that pregnant women infected with SARS-CoV-2 have more infection-related obstetric morbidity. This hypothesis merits evaluation of a causal association in further research

Subcutaneous anti-COVID-19 hyperimmune immunoglobulin for prevention of disease in asymptomatic individuals with SARS-CoV-2 infection: a double-blind, placebo-controlled, randomised clinical trialResearch in context

Summary: Background: Anti-COVID-19 hyperimmune immunoglobulin (hIG) can provide standardized and controlled antibody content. Data from controlled clinical trials using hIG for the prevention or treatment of COVID-19 outpatients have not been reported. We assessed the safety and efficacy of subcutaneous anti-COVID-19 hyperimmune immunoglobulin 20% (C19-IG20%) compared to placebo in preventing development of symptomatic COVID-19 in asymptomatic individuals with SARS-CoV-2 infection. Methods: We did a multicentre, randomized, double-blind, placebo-controlled trial, in asymptomatic unvaccinated adults (≥18 years of age) with confirmed SARS-CoV-2 infection within 5 days between April 28 and December 27, 2021. Participants were randomly assigned (1:1:1) to receive a blinded subcutaneous infusion of 10 mL with 1 g or 2 g of C19-IG20%, or an equivalent volume of saline as placebo. The primary endpoint was the proportion of participants who remained asymptomatic through day 14 after infusion. Secondary endpoints included the proportion of individuals who required oxygen supplementation, any medically attended visit, hospitalisation, or ICU, and viral load reduction and viral clearance in nasopharyngeal swabs. Safety was assessed as the proportion of patients with adverse events. The trial was terminated early due to a lack of potential benefit in the target population in a planned interim analysis conducted in December 2021. ClinicalTrials.gov registry: NCT04847141. Findings: 461 individuals (mean age 39.6 years [SD 12.8]) were randomized and received the intervention within a mean of 3.1 (SD 1.27) days from a positive SARS-CoV-2 test. In the prespecified modified intention-to-treat analysis that included only participants who received a subcutaneous infusion, the primary outcome occurred in 59.9% (91/152) of participants receiving 1 g C19-IG20%, 64.7% (99/153) receiving 2 g, and 63.5% (99/156) receiving placebo (difference in proportions 1 g C19-IG20% vs. placebo, −3.6%; 95% CI -14.6% to 7.3%, p = 0.53; 2 g C19-IG20% vs placebo, 1.1%; −9.6% to 11.9%, p = 0.85). None of the secondary clinical efficacy endpoints or virological endpoints were significantly different between study groups. Adverse event rate was similar between groups, and no severe or life-threatening adverse events related to investigational product infusion were reported. Interpretation: Our findings suggested that administration of subcutaneous human hyperimmune immunoglobulin C19-IG20% to asymptomatic individuals with SARS-CoV-2 infection was safe but did not prevent development of symptomatic COVID-19. Funding: Grifols